Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome
Postural orthostatic tachycardia syndrome (POTS) is a complex, multifaceted disorder that impairs functional status and quality of life. Current pharmacological treatments are limited.
This study investigated the effect of ivabradine (selective blocker of the Ifunny channel in the sinoatrial node) on heart rate, quality of life (QOL), and plasma norepinephrine (NE) levels in patients with hyperadrenergic POTS defined by plasma NE >600 pg/ml and abnormal tilt table test.
In total, 22 patients with hyperadrenergic POTS as the predominant subtype completed a randomized, double-blinded, placebo-controlled, crossover trial with ivabradine. Patients were randomized to start either ivabradine or placebo for 1 month, and then were crossed over to the other treatment for 1 month. Heart rate, QOL, and plasma NE levels were measured at baseline and at the end of each treatment month.
The average age was 33.9 ± 11.7 years, 95.5% were women (n = 21), and 86.4% were White (n = 23). There was a significant reduction in heart rate between placebo and ivabradine (p < 0.001). Patients reported significant improvements in QOL with RAND 36-Item Health Survey 1.0 for physical functioning (p = 0.008) and social functioning (p = 0.021). There was a strong trend in reduction of NE levels upon standing with ivabradine (p = 0.056). Patients did not experience any significant side-effects, such as bradycardia or hypotension, with ivabradine.
Ivabradine is safe and effective in significantly improving heart rate and QOL in patients with hyperadrenergic POTS as the predominant subtype.
Postural orthostatic tachycardia syndrome (POTS) is a poorly understood, complex multisystem clinical disorder that predominantly affects women. The majority of these patients are young, Caucasian women (1,2), and current prevalence estimates range from 500,000 to 3 million patients nationwide (2). Patients with POTS experience a wide spectrum of debilitating symptoms (2–4). Upon assuming a standing position from a supine position, patients have an increase in heart rate by 30 beats/min. This is often accompanied by lightheadedness, palpitations, dyspnea, headaches, and near-syncope (3–8). This positional elevation in heart rate causes extreme fatigue and weakness, which impairs their ability to remain upright and perform daily tasks. Ultimately, this reduces a patient’s functional status and quality of life (QOL). These symptoms may improve when patients return to a recumbent position (2). Unfortunately, many patients become bedridden due to the limited efficacy of current therapies.
POTS is currently understood to be composed of 5 subtypes: 1) hyperadrenergic; 2) neuropathic; 3) hypovolemic; 4) joint-hypermobility-related; and 5) immune-related. However, these subtypes are not mutually exclusive, as symptoms and treatments often overlap. The hyperadrenergic subtype, which comprises up to 50% of POTS (5), is characterized by abnormal sympathetic nervous system activation. The body is in a constant “flight or fight” mode, which results in abnormal responses including elevated heart rate and decreased perfusion of organs. For the hyperadrenergic subtype, supine and standing plasma norepinephrine (NE) levels are markedly elevated compared with healthy patients. In healthy patients, supine plasma NE has been reported to be approximately 200 pg/ml and doubles to 400 to 500 pg/ml upon standing (9–11). In patients with POTS, however, NE levels can triple or quadruple upon standing (405 to 1,207 pg/ml) (2,10,11).
There are currently no Class I recommendations for the treatment of POTS (3,5,12). Ivabradine has a unique and selective mechanism of action, which specifically blocks the Ifunny channel of the sinoatrial (SA) node, consequently lowering heart rate directly without lowering blood pressure (BP). The SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study showed that ivabradine reduces heart failure hospitalizations by lowering heart rate (13). The SHIFT trial investigators hypothesized that isolated heart rate reduction without BP lowering with ivabradine unloads the left ventricle and reverses adverse cardiac remodeling that contributes to heart failure (14). In the United States, ivabradine is approved by the U.S. Food and Drug Administration for patients with systolic heart failure with Class IIa recommendation to reduce heart failure hospitalizations (15,16). Although ivabradine has a Class IIa recommendation for inappropriate sinus tachycardia, it is not included in the current guidelines for POTS (5).
Ivabradine may be particularly useful in patients with a component of hyperadrenergic POTS by selectively inhibiting the SA node and decreasing heart rate. Many prior small studies and case reports (17–29) have shown the promising potential of ivabradine for POTS. We have conducted the first randomized, double-blinded, placebo-controlled, crossover trial in which patients with hyperadrenergic POTS as the predominant subtype were started on ivabradine and compared with placebo.
This clinical study was approved by the University of California, San Diego Institutional Review Board and registered on ClinicalTrials.gov ( NCT03182725). All patients provided informed written consent.
POTS is a clinical disorder classified by: 1) symptoms upon standing such as lightheadedness, palpitations, tremors, weakness, blurry vision, and fatigue; 2) increase in heart rate ≥30 beats/min upon postural change from recumbent to upright position within 10 min of standing; and 3) absence of orthostatic hypotension (3,5,8,30). Hyperadrenergic POTS, a subtype of POTS, is defined as an elevation in NE >600 pg/ml upon standing and a systolic BP increase of >10 mm Hg when standing upright for 10 min (5). We did not use the systolic BP criteria, as we recognized clinically that many patients had overlapping subtypes (e.g., hyperadrenergic and hypovolemic that resulted in lack of systolic BP increase). A positive head-up tilt table test (HUTT) (heart rate ≥30 beats/min) and NE (≥600 pg/ml) were required for study enrollment.
The study design is presented in Figure 1. Utilizing a randomized, double-blinded, placebo-controlled crossover design, eligible patients with hyperadrenergic POTS were started on either ivabradine or placebo for 1 month, underwent a 1-week washout period and were crossed over to the other treatment for 1 month (Figure 1). Study participation lasted approximately 2.5 months with 7 clinic visits.
Randomization and blinding
All patients who completed the study took both ivabradine and placebo, but at different time points. The order in which they received the treatment, either ivabradine first or placebo first, was randomly assigned with a web-based randomization table provided by the study statistician (S.G.). Both the research team and patients were blinded to the treatment and treatment order. Patients were unblinded upon study completion or withdrawing.
Patients were screened and recruited from University of California, San Diego cardiology clinics from 2018 to 2020. Patients age 18 to 65 years with a diagnosis of hyperadrenergic POTS as defined by baseline standing NE >600 pg/ml (5) and heart rate increase >30 beats/min on HUTT were enrolled. Patients with a resting heart rate <60 beats/min, atrial fibrillation, or supraventricular tachycardia were excluded. Women who were pregnant and/or breastfeeding were excluded. Women of childbearing age were required to use contraception during the study. Patients on medications such as heart rate modulators (beta-blockers, calcium-channel blockers), cholinesterase inhibitors (pyridostigmine), vasoconstrictors (midodrine, octreotide, droxidopa, stimulants), sympatholytics (clonidine, methyldopa), or blood volume increasers (fludrocortisone, desmopressin, salt supplementation) for their POTS symptoms were required to undergo a 1-week washout before their screening visit. Although patients had symptoms of orthostatic intolerance, none of the patients had orthostatic hypotension at enrollment.
Head-up tilt testing
The HUTT was conducted in the mornings with patients fasting for 8 h by study physicians (J.C.H. and P.R.T.) at the baseline visit. Heart rate and BP were monitored continuously. Patients were instructed to report any symptoms. HUTT was abnormal if patients had an increase in heart rate by at least 30 points from baseline, and experienced symptoms of orthostatic intolerance (5,31).
To obtain plasma NE levels, patients lay in a quiet dark room supine for 15 min. At the end of 15 min, blood was drawn. Then, patients were asked to stand upright for 15 min, at which point blood was drawn again (4,6). Blood was collected in chilled lithium heparin vacuum tubes for the catecholamine panel. Plasma was separated by refrigerated centrifugation and frozen within an hour of collection. Samples were analyzed using quantitative high-performance liquid chromatography. Plasma NE levels were obtained at baseline, end of ivabradine month, and end of placebo month.
After randomization, patients were started on a 5-mg twice daily (bid) dose of ivabradine or placebo. In 6 cases, a modified, lower dose of 2.5-mg bid was initiated due to the principal investigator’s (P.R.T.) evaluation of the patient’s orthostatic vitals monitoring (OVM). Patients were instructed to take the medication with meals, once in the morning and once in the evening. After 2 weeks, patients returned for OVM so the principal investigator (P.R.T.) could determine if dose adjustments were needed. To conduct OVM, patients lay supine for at least 3 min to establish a baseline. At the end of 3 min, heart rate and BP were measured. Then, patients stood for at least 3 min; at the end of 3 min, their standing heart rate and BP were measured.
Medication dose was changed according to the patient’s heart rate response and tolerance of current dose. If the resting supine heart rate was >70 beats/min, doses were increased to 7.5 mg bid (or 5 mg bid for patients initiated on a 2.5-mg dose). If the resting supine heart rate was <70 beats/min, there was no increase in dose. All dose titrations were done by the study principal investigator (P.R.T.). At 2 weeks after the initial titration visit, patients returned to the clinic to repeat NE bloodwork and OVM. At this visit, patients stopped the medication and commenced a 1-week washout period. When the washout period ended, they returned to the clinic to initiate the second month of treatment. As part of the crossover design, patients on placebo were switched to ivabradine, and patients on ivabradine were switched to placebo. The previously mentioned protocol was followed for the 2-week titration and end-of-month final visit.
QOL was assessed using the RAND 36-Item Health Survey 1.0 (SF-36) questionnaire upon enrollment in the study (baseline), end of placebo month, and end of ivabradine month. SF-36 questions are subdivided into 8 distinct categories: physical functioning, physical health, emotional problems, vitality, emotional well-being, social functioning, pain, and general health.
The primary outcome was change in heart rate after 1 month on ivabradine. The secondary outcome was a change in self-reported QOL measured by the SF-36 after 1 month of ivabradine. As an exploratory outcome, changes in plasma NE levels were also assessed after 1 month on ivabradine. Heart rate, QOL, and NE were all assessed at 3 time points: baseline, end of placebo month, and end of ivabradine month.
Descriptive statistics and exploratory graphing, such as frequencies, means, SDs, box and whisker plots, stem and leaf diagrams, and scatter plots, were used to assess the normality of the data in terms of the presence of skew and/or outliers. Furthermore, z-score for skewness and kurtosis were computed for all outcomes. The following variables were skewed: pre-phase (heart rate delta), baseline (physical health, body mass index), placebo phase (ne supine), washout phase (standing systolic), active titration (standing systolic), and active (supine systolic, standing systolic). Log transformation was done to normalize the following outcomes: washout phase (standing systolic), active (supine systolic, standing systolic), and baseline (physical health, body mass index). Final analyses for heart rate and quality of life were repeated using the original data (not log-transformed) and using nonparametric methods with similar results. All reported analyses were performed with the original non–log-transformed data format. The comparability of the baseline values and treatment order were tested with analyses of variance (ANOVAs) for continuous variables or chi-square analyses for dichotomous variables. Data was inspected for bias due to dropouts, missing data, and treatment order. Treatment order/carryover effect was tested using 2 methods. In the first method, treatment order was added as an independent factor to the repeated measures (RM)-ANOVA model, and all interactions were tested. In the second method, the approach by Wellek and Blettner (32) was used. None of the interactions or Student’s t-test values were significant, indicating a lack of any carryover or treatment-order effect. Hypotheses were tested using RM-ANOVA. RM-ANOVA with 2 within factors were used: 1) treatment with 2 levels: placebo and ivabradine; and 2) body position with 2 levels: supine and standing. The body position factor was nested within the treatment factor. RM-ANOVA models with 1 within factor of treatment were used when only 1 position was compared across treatments. Patients were also stratified based on the baseline NE standing position values into 2 groups, high NE (600 to 1,000 pg/ml) and very high NE (≥1,000 pg/ml), and RM-ANOVA was repeated with addition of the NE baseline grouping factor comparing placebo with ivabradine across 2 positions. Treatment effect estimates with corresponding p values were based within patient comparisons. All statistical tests were 2-tailed. All available data was used in analyses, and no patients were excluded due to missing data. SF-36 was scored based on RAND instructions (33). Differences were considered statistically significant if a p value of 0.05 or less was obtained using SPSS version 26 (IBM, Armonk, New York) (34).
Baseline demographics and characteristics of all patients are shown in Table 1. In total, 37 patients (average age 32.5 ± 11.4 years; n = 35 women) were screened, 10 failed screening (7 did not meet NE criteria, and 3 did not meet criteria for POTS by HUTT), and 1 withdrew prior to randomization. Of the 26 randomized patients, 22 patients completed the study and were included in the final data analysis (Figure 2). Of the 4 patients who withdrew after randomization, 1 dropped out on placebo due to other health concerns, and 3 dropped out while on ivabradine due to nausea and drowsiness after 3 days, fatigue after 21 days, and phosphenes after 4 days. These side-effects were among the typical side-effects associated with ivabradine, such as phosphenes, tiredness, and palpitations (12,35,36). None of our patients experienced any worsening of POTS symptoms. Ivabradine was not stopped by the study investigators due to adverse events in any patient. There were no significant demographic differences between those who dropped out and those who completed the study.
|Randomized to Placebo First (n = 16)||Randomized to Ivabradine First (n = 6)|
|Age, yrs||35.6 ± 10.6||29.3 ± 14.4|
|Weight, lbs||142.7 ± 38.6||142.8 ± 32.4|
|Body mass index, kg/m2||24.1 ± 7.1||22.3 ± 4.7|
513.6 ± 149.4
1,143.4 ± 351.7
328.8 ± 96.0
842.3 ± 221.7
|Heart rate, beats/min|
77.4 ± 13.4
101.1 ± 19.0
74.8 ± 14.9
111.2 ± 14.2
|Systolic blood pressure, mm Hg|
121.8 ± 17.2
122.9 ± 24.7
115.8 ± 11.8
117.3 ± 12.5
|Diastolic blood pressure, mm Hg|
78.8 ± 13.8
82.3 ± 16.9
76.2 ± 14.5
78.8 ± 9.9
Of the 26 randomized patients, the majority had symptoms for 1 to 3 years prior to the diagnosis of POTS. Thirty percent of patients had a history of unexplained syncope. Also, 5 patients had a diagnosis of anxiety/panic disorder: 3 patients had both anxiety and depression, and 1 had depression.
A total of 7 patients started on 2.5 mg bid, 16 on 5 mg bid, and 1 on 5 mg in the morning and 2.5 mg in evening. At their ivabradine titration visit, 1 patient decreased dose from 5 to 2.5 mg bid due to complaints of self-reported bradycardia, and 2 patients’ doses were increased to 7.5 mg bid due to elevated supine and standing heart rate.
Primary outcome: heart rate
The effect of ivabradine on heart rate is shown in Table 2. Ivabradine significantly reduced heart rate upon standing compared with placebo (p < 0.001). We also found that the characteristic positional surge in heart rate from supine to standing was significantly blunted with ivabradine compared to baseline (p = 0.001). No patients experienced symptomatic bradycardia while on ivabradine.
|Baseline||Ivabradine||Placebo||p Value||Cohen’s D||95% CI|
|Supine heart rate, beats/min||73.6 ± 11.7||64.9 ± 6.5||77.5 ± 12.8||0.001∗||1.26||0.706–1.820|
|Standing heart rate, beats/min||95.1 ± 16.8||77.9 ± 9.3||94.2 ± 16.2||0.001∗||1.05||0.544–1.58|
|Delta heart rate (standing vs. supine), beats/min||21.4 ± 15.3||13.1 ± 8.6||17.0 ± 10.4||0.001∗||0.753||0.300–1.250|
No clinically significant hypotension was found in patients on ivabradine (Supplemental Table 1). We also found no clinically significant statistical difference in systolic or diastolic BP between placebo and ivabradine, or between postural changes.
Secondary outcome: quality of life
Compared with placebo, significant improvements were seen in QOL measures of physical functioning (p = 0.008) and social functioning (p = 0.021) (Table 3). As expected, there were no significant differences between baseline and placebo.
|Baseline||Ivabradine||Placebo||p Value||Cohen’s D||95% CI|
|Physical functioning||41.6 ± 21.9||53.4 ± 27.0||44.1 ± 22.4||0.008∗||0.570||0.308–0.894|
|Physical health||13.1 ± 23.5||38.9 ± 40.0||26.1 ± 34.3||0.159||0.223||0.000–0.575|
|Emotional problems||53.4 ± 45.0||62.1 ± 43.2||57.2 ± 44.7||0.567||0.000||0.000–0.378|
|Vitality||19.0 ± 16.9||30.8 ± 24.4||23.8 ± 20.5||0.102||0.289||0.000–0.628|
|Emotional well-being||61.9 ± 16.5||63.9 ± 17.4||60.0 ± 18.8||0.104||0.286||0.000–0.626|
|Social functioning||43.2 ± 28.7||56.6 ± 31.1||43.8 ± 27.3||0.021∗||0.477||0.228–0.800|
|Pain||48.7 ± 33.2||53.4 ± 30.9||49.2 ± 30.7||0.232||0.146||0.000–0.525|
|General health||33.5 ± 18.5||33.1 ± 19.3||32.7 ± 18.2||0.897||0.000||0.000–0.046|
Ivabradine did not lower supine NE level (p = 0.316) or the standing NE level (p = 0.076) (Table 4). There was a strong trend for the decrease in NE levels from supine to standing for ivabradine compared with placebo (p = 0.056). We did note a significant reduction (p = 0.030) in NE levels from supine to standing on ivabradine (442.3 ± 232.6 pg/ml) compared with baseline (598.1 ± 316.2 pg/ml).
|Baseline||Ivabradine||Placebo||p Value||Cohen’s D||95% CI|
|Supine NE, pg/ml||459.43 ± 161.7||472.0 ± 219.3||523.4 ± 223.0||0.316||0.0493||0.000–0.625|
|Standing NE, pg/ml||1,046.0 ± 346.5||914.3 ± 358.5||1,055.4 ± 371.2||0.076||0.337||0.000–0.829|
|Delta NE (standing vs. supine), pg/ml||598.1 ± 316.2||442.3 ± 232.6||532.1 ± 259.0||0.056|
Stratification of NE level on effect of ivabradine
When baseline (before study enrollment) standing NE was stratified into high NE (600 to 1,000 pg/ml) and very high NE (≥1,000 pg/ml), 11 patients were in the high NE and 10 patients in the very high NE group (Table 5). Those in the very high NE group had a greater magnitude of reduction in standing NE with ivabradine compared with those in the high NE group (p = 0.026) (Central Illustration).
|Placebo||Ivabradine||p Value||Cohen’s D||95% CI|
|High NE supine, pg/ml||503.5 ± 299.3||433.7 ± 240.1||0.740||0.000||0.000–0.403|
|Very high NE supine, pg/ml||545.3 ± 100.0||514.1 ± 197.6|
|High NE standing, pg/ml||872.0 ± 352.4||803.6 ± 373.7||0.325||0.032||0.000–0.581|
|Very high NE standing, pg/ml||1,257.2 ± 286.0||1,036.1 ± 314.7|
|Delta (Standing vs. supine) in high NE, pg/ml||368.5 ± 171.2||369.9 ± 188.9||0.026∗||0.477||0.127–0.904|
|Delta (Standing vs. supine) in very high NE, pg/ml||711.9 ± 218.9||522.0 ± 259.0|
Treatment order/carryover effect
Two different methods were used to examine the treatment order/carryover effect (see the Statistical Methods section). When treatment order was added to the RM-ANOVA model as an independent factor, none of the interactions of treatment order were significant (Supplemental Table 2). Similarly, none of the Student’s t-test values were significant. These analyses indicated no carryover or treatment order effect.
To date, this is the first study of its kind, to the best of our knowledge, to investigate the effects of ivabradine in patients with hyperadrenergic POTS as the predominant subtype in a randomized, double-blinded, placebo-controlled, crossover trial. We show that ivabradine is safe and effective in lowering the heart rate of patients with hyperadrenergic POTS and improves QOL.
There are currently no Class I pharmacological recommendations for POTS, and the current recommendations for POTS, such as midodrine and fludrocortisone, are Class IIb recommendations (5,12). Additionally, medications used to lower heart rate, such as beta-blockers and calcium-channel blockers concurrently lower BP, which can limit their use. Ivabradine is a specific cardioselective agent that inhibits the Ifunny channel of the SA node and lowers heart rate directly without lowering BP. Similar to the SHIFT trial, which showed 15-point mean heart rate reduction with ivabradine in patients with heart failure (13), we saw a 13-point mean heart rate reduction in patients with hyperadrenergic POTS.
This study showed that patients who were treated with ivabradine had lower heart rate during treatment compared with when they were taking placebo (p < 0.001). Additionally, the typical surge in heart rate that occurs in patients with POTS upon standing was also significantly blunted with ivabradine compared with baseline (p = 0.001). Moreover, these significant reductions in heart rate with ivabradine were also associated with improvements in QOL and NE levels, which had not been demonstrated with prior studies.
According to the SHIFT trial with systolic heart failure patients, the magnitude in heart rate reduction with ivabradine depended on the baseline heart rate (13). Patients with POTS in this study experienced a lower heart rate upon standing while on ivabradine (77.9 ± 9.3 beats/min) versus placebo (94.2 ± 16.2 beats/min). When we examined the change in heart rate that occurs from supine to standing, patients who were on ivabradine had a smaller rise in heart rate (13.1 ± 8.6 beats/min). These reductions in heart rate both in a standing position and when changing positions are within previously reported ranges (11 to 17 beats/min) (26,28,29,35). The improvement in heart rate with a therapeutic dose range of 5 to 15 mg/day is also similar to prior studies (26–29,35). Only 1 (4.5%) patient in our study reported phosphenes, which is also similar to the reported range of 4.5% to 18% (27–29). As expected, there were no clinically significant differences in BP when ivabradine was compared with baseline or placebo.
Prior studies examining the effect of ivabradine in POTS patients were not randomized and did not selectively enroll the hyperadrenergic POTS subtype. Ruzieh et al. (29) showed significant reductions in standing heart rate on ivabradine (95.1 ± 13.7 beats/min) compared with baseline (107.4 ± 14.1 beats/min) in 49 patients with POTS. However, this was a retrospective cohort study over 3 to 12 months without QOL assessment (29,35). Similarly, Delle Donne et al. (28) showed significant decreases in resting heart rate with ivabradine (71.3 ± 16.5 beats/min) compared with baseline (82.5 ± 13.6 beats/min) in a retrospective cohort study with 22 POTS patients over 1 to 17 months, but without assessing QOL (28,35). In a retrospective cohort study conducted by McDonald et al. (27) over 2 to 29 months with 20 POTS patients, symptom improvement was reported with ivabradine (utilizing a study-specific assessment tool), but the magnitude of heart rate reduction was not quantified (27,35). Although Barzilai and Jacob (26) showed the benefit of ivabradine in 8 patients with POTS, this was a prospective open-label study with only a single dose of ivabradine administration (26,35).
The secondary outcome of this study was the effect of ivabradine on QOL. The severe tachycardia patients with POTS experience limits their functional status, as they are unable to remain upright or walk for long periods of time. It has been reported that over 25% of patients with POTS are unable to work (6,37). In addition to the reduced QOL, many patients have concomitant depression and anxiety (37–43). Patients with POTS often have many other comorbidities and are on multiple medications with numerous side-effects, which may further decrease QOL. In our study with 22 POTS patients, there were statistically significant improvements in QOL measures. Compared with placebo, patients reported significant improvements in physical functioning (p = 0.008) and social functioning (p = 0.021). This improvement in QOL is remarkable because this was achieved with ivabradine alone, and patients were not on other medications for POTS. Even though prior studies with ivabradine did not assess QOL, Moon et al. (44) did show improvements in QOL with beta-blockers. However, beta-blockers alone showed improvement in the physical components of SF-36, and the addition of pyridostigmine was needed to improve the mental component of SF-36 (44). In our study with ivabradine alone, we noted improvements in both the physical and mental components of SF-36. This further reinforces the improved QOL patients experienced with ivabradine.
Furthermore, based on our review of the published data, plasma NE levels were not examined with prior ivabradine studies (17–29). Although plasma NE levels were reported with clonidine administration in dysautonomia, it was not statistically significant (45). This is the first study to demonstrate statistically significant improvements with postural changes in heart rate and a strong trend toward improving plasma NE upon standing with ivabradine in patients with hyperadrenergic POTS as the predominant subtype. The reduction in plasma NE levels with ivabradine between supine and standing positions was nearly significant compared with placebo (p = 0.056). Clinically, patients are most symptomatic when changing positions, and we have shown significant reductions in NE levels upon standing with ivabradine (p = 0.030). Moreover, this study shows that patients with standing plasma NE levels ≥1,000 pg/ml at baseline had a larger magnitude of reduction in NE levels with ivabradine than those with baseline standing NE levels 600 to 1,000 pg/ml (p = 0.026). Since POTS is a heterogenous disorder with overlapping subtypes, stratification by plasma NE levels could potentially be a clinically useful tool in determining which patients will derive the most benefit from ivabradine.
Due to its heart rate reduction without lowering BP, and possible down-regulation of the sympathetic nervous system as evidenced by lower NE levels, ivabradine has clinical benefit in patients with hyperadrenergic POTS as the predominant subtype. Ivabradine may also provide an additional benefit if combined with other pharmacological agents. Further research is warranted for the use of ivabradine in other subtypes of POTS.
One potential limitation of this study is the small sample size; however, a small study sample would be susceptible to false-negative (type II) error, whereas we found several statistically significant results. Another limitation is that although the study investigators and patients were blinded to the intervention, many patients noticed significant differences and suspected that they were on ivabradine. Additionally, patients were only on 1 month of ivabradine, and a longer study duration may be warranted to assess potential long-term effects.
POTS is a debilitating multifactorial clinical disorder with complex pathophysiology that significantly impairs QOL for patients. This study shows that ivabradine provides notable improvements in heart rate, QOL, and NE in patients with hyperadrenergic POTS.
COMPETENCY IN MEDICAL KNOWLEDGE: Ivabradine selectively inhibits sinoatrial node automaticity, decreasing heart rate without lowering BP. In patients with hyperadrenergic POTS, this alleviates symptoms and improves QOL.
TRANSLATIONAL OUTLOOK: Larger and longer-term studies are needed to identify the underlying causes of hyperadrenergic POTS; assess the durability of the ivabradine treatment effect; and define optimum timing, intensity, and duration of therapy.
Funding Support and Author Disclosures
A grant from Amgen was received to conduct this investigator-initiated clinical trial. No financial support was received in the writing of this paper. Dr. Taub has served as a consultant for Amgen, Bayer, Esperion, Boehringer Ingelheim, Novo Nordisk, and Sanofi; is a shareholder in Epirium Bio; and has received research grants from the NIH (R01 DK118278-01 and R01 HL136407), the American Heart Association (SDG #15SDG2233005), and the Department of Homeland Security/FEMA (EMW-2016-FP-00788). Dr. Hsu has served as a consultant for Medtronic, Abbott, Boston Scientific, Biotronik, Biosense Webster, Zoll Medical, Pfizer, Bristol Myers Squibb, and Janssen Pharmaceuticals; has received research grants from Biosense Webster and Biotronik; and is a shareholder in Acutus Medical and Vektor Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Abbreviations and Acronyms
head-up tilt table test
orthostatic vitals monitoring
postural orthostatic tachycardia syndrome
quality of life
RAND 36-Item Health Survey 1.0
1. "The face of postural tachycardia syndrome—insights from a large cross-sectional online community-based survey". J Intern Med 2019;286:438-448.
2. "Postural orthostatic tachycardia syndrome: mechanisms and new therapies". Annu Rev Med 2020;71:235-248.
3. "Postural orthostatic tachycardia syndrome: prevalence, pathophysiology, and management". Drugs 2018;78:983-994.
4. "Postural tachycardia syndrome (POTS)". Circulation 2013;127:2336-2342.
5. "2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope". Heart Rhythm 2015;12:e41-e63.
6. "Postural tachycardia syndrome: beyond orthostatic intolerance". Curr Neurol Neurosci Rep 2015;15:60.
7. "What is brain fog? An evaluation of the symptom in postural tachycardia syndrome". Clin Auton Res 2013;23:305-311.
8. "Postural orthostatic tachycardia syndrome: JACC focus seminar". J Am Coll Cardiol 2019;73:1207-1228.
9. "Effect of standing on neurohumoral responses and plasma volume in healthy subjects". J Appl Physiol 1998;84:914-921.
10. "Abnormalities of angiotensin regulation in postural tachycardia syndrome". Heart Rhythm 2011;8:422-428.
11. "Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome". Circulation 2005;111:1574-1582.
12. "Pharmacotherapy for postural tachycardia syndrome". Auton Neurosci 2018;215:28-36.
13. "Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study". Lancet 2010;376:875-885.
14. "Prognostic and symptomatic benefits with ivabradine: lessons from the SHIFT trial". Eur Heart J Suppl 2015;17:G30-G36.
15. "Ivabradine in congestive heart failure: patient selection and perspectives". Cureus 2019;11:e4448.
16. "The clinical use of ivabradine". J Am Coll Cardiol 2017;70:1777-1784.
17. "Cooccurrence of postural orthostatic tachycardia syndrome with two different clinical entities". Case Rep Pediatr 2016;2016:8542158.
18. "Symptom improvement in postural orthostatic tachycardia syndrome with the sinus node blocker ivabradine". Europace 2007;9:1202.
19. "Treatment of inappropriate sinus tachycardia with ivabradine in a patient with postural orthostatic tachycardia syndrome and a dual chamber pacemaker". Pacing Clin Electrophysiol 2009;32:131-133.
20. "Use of ivabradine in postural orthostatic tachycardia syndrome". J Atr Fibrillation 2010;3:273.
21. "Atrioventricular node ablation and pacemaker implantation for recurrent syncope in a patient with postural tachycardia syndrome (POTS)". J Cardiovasc Electrophysiol 2011;22:1284-1287.
22. "Successful use of ivabradine in a case of exaggerated autonomic dysfunction". Turk Kardiyol Dern Ars 2010;38:285-289.
23. "Is ivabradine a wonder drug for atypical POTS?"BMJ Case Rep 2019;12:e227789.
24. "Potentially new indication of ivabradine: treatment of a patient with postural orthostatic tachycardia syndrome". Open Cardiovasc Med J 2010;4:166-167.
25. "POTS following traumatic stress: interacting central and intracardiac neural control?"J Diabetes Complications 2015;29:459-461.
26. "The effect of ivabradine on the heart rate and sympathovagal balance in postural tachycardia syndrome patients". Rambam Maimonides Med J 2015;6:e0028.
27. "Single centre experience of ivabradine in postural orthostatic tachycardia syndrome". Europace 2011;13:427-430.
28. "Ivabradine in postural orthostatic tachycardia syndrome: preliminary experience in children". Am J Cardiovasc Drugs 2018;18:59-63.
29. "Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience". Pacing Clin Electrophysiol 2017;40:1242-1245.
30. "Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome". Auton Neurosci 2011;161:46-48.
31. "The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing". Pacing Clin Electrophysiol 1997;20:2205-2212.
32. "On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications". Dtsch Arztebl Int 2012;109:276-281.
33. "36-Item Short Form Survey (SF-36) scoring instructions". Available at: https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/scoring.html. Accessed
June 21, 2020.
34. "IBM Corp. Released 2019. IBM SPSS Statistics for Windows, Version 26.0". Armonk, NY: IBM Corp.
35. "Ivabradine for the treatment of postural orthostatic tachycardia syndrome: a systematic review". Am J Cardiovasc Drugs 2018;18:195-204.
36. U.S. Food and Drug Administration. "Highlights of prescribing information: Corlanor". Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206143Orig1s000lbl.pdf. Accessed
June 26, 2020.
37. "Postural tachycardia syndrome". Circulation 2008;117:2814-2817.
38. "Cognitive and psychological issues in postural tachycardia syndrome". Auton Neurosci 2018;215:46-55.
39. "Cognitive function, health-related quality of life, and symptoms of depression and anxiety sensitivity are impaired in patients with the postural orthostatic tachycardia syndrome (POTS)". Front Physiol 2014;5:230.
40. "Cognitive dysfunction in postural tachycardia syndrome". Clin Sci 2015;128:39-45.
41. "Orthostatic intolerance symptoms are associated with depression and diminished quality of life in patients with postural tachycardia syndrome". Health Qual Life Outcomes 2016;14:144.
42. "Psychiatric profile and attention deficits in postural tachycardia syndrome". J Neurol Neurosurg Psychiatry 2009;80:339-344.
43. "Postural orthostatic tachycardia syndrome". Postgrad Med J 2007;83:478-480.
44. "Efficacy of propranolol, bisoprolol, and pyridostigmine for postural tachycardia syndrome: a randomized clinical trial". Neurotherapeutics 2018;15:785-795.
45. "Effects of long-term clonidine administration on the hemodynamic and neuroendocrine postural responses of patients with dysautonomia". Chest 1983;83:436-438.
AppendixSupplemental Tables 1 and 2
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.